Table 2

Overview of randomised controlled trials included in the networks evaluating clinical efficacy in bDMARD-naïve patients with PsA

Study acronymInterventionsNo. of patients*Time point (weeks)Primary outcomeIncluded in efficacy networks
ACTIVE33–35Apremilast 30 mg PO BID11016ACR20 at week 16ACR
Placebo109
ADEPT36–38Adalimumab 40 mg SC Q2W15112ACR20 at week 12; mTSS score change from baseline to week 24ACR, PASI, PsARC
Placebo162
ASTRAEA39 40Abatacept 125 mg SC Q1W21312ACR20 at week 24ACR
Placebo211
FUTURE 231 38 41–44Secukinumab 150 mg SC Q4W10012ACR20 at week 24ACR†, PASI†, PsARC†
Secukinumab 300 mg SC Q4W100
Placebo98
FUTURE 345Secukinumab 150 mg SC Q4W13812ACR20 at week 24ACR
Secukinumab 300 mg SC Q4W139
Placebo137
FUTURE 446Secukinumab 150 mg SC Q4W11416ACR20 at week 16ACR, PASI†
Placebo114
FUTURE 5 47 48Secukinumab 150 mg SC Q4W22012/16‡ACR20 at week 16ACR, PASI†
Secukinumab 300 mg SC Q4W222
Placebo332
49Adalimumab 40 mg SC Q2W5112ACR20 at week 12ACR, PsARC
Placebo49
GO-REVEAL50 51Golimumab 50 mg SC Q4W14614ACR20 at week 14ACR, PASI, PsARC
Placebo113
IMPACT52Infliximab 5 mg/kg IV Q8W5214/16/16‡ACR20 at week 16ACR, PASI, PsARC
Placebo52
IMPACT 253 54Infliximab 5 mg/kg IV Q8W10014ACR20 at week 14ACR, PASI, PsARC
Placebo100
M14-197§55 56Adalimumab 40 mg SC Q2W7212ACR20 at week 12 
Placebo24
57Etanercept 25 mg BIW/50 mg Q1W3012PsARC at week 12ACR, PASI, PsARC
Placebo30
58Etanercept 25 mg BIW/50 mg Q1W10112ACR20 at week 24ACR, PsARC
Placebo104
59Abatacept 10 mg/kg IV Q4W4012ACR20 at week 24ACR†, PASI†
Placebo42
OPAL BEYOND§60–62Tofacitinib 5 mg PO BID13112ACR20 at week 12; HAQ-DI change from baseline to week 12 
Placebo131 
OPAL BROADEN62–65Adalimumab 40 mg SC Q2W10612ACR20 at week 12; HAQ-DI change from baseline to week 12ACR, PASI, PsARC
Tofacitinib 5 mg PO BID107
Placebo105
PALACE 138 66–68Apremilast 30 mg PO BID16816ACR20 at week 16ACR, PASI, PsARC
Placebo168
PALACE 269Apremilast 30 mg PO BID16216ACR20 at week 16ACR, PASI†, PsARC†
Placebo159
PALACE 370Apremilast 30 mg PO BID16716ACR20 at week 16ACR, PASI†
Placebo169
PSUMMIT 138 71 72Ustekinumab 45 mg SC Q12W20512ACR20 at week 24ACR, PASI
Ustekinumab 90 mg SC Q12W204
Placebo206
PSUMMIT 2 38 73Ustekinumab 45 mg SC Q12W10312ACR20 at week 24ACR, PASI
Ustekinumab 90 mg SC Q12W105
Placebo104
RAPID-PsA38 74–78Certolizumab pegol (pooled doses)27312ACR20 at week 12; mTSS change from baseline to week 24ACR, PASI, PsARC†
Placebo136
SPIRIT-P179–84Ixekizumab 80 mg SC Q2W10312ACR20 at week 24ACR, PASI, PsARC
Ixekizumab 80 mg SC Q4W107
Adalimumab 40 mg SC Q2W101
Placebo106
SPIRIT-P2§85–90Ixekizumab 80 mg SC Q2W123ACR20 at week 24 
Ixekizumab 80 mg SC Q4W122
Placebo118

  • *Patient numbers are for the intent-to-treat population.

  • †Data presented for the overall population of bDMARD-naïve and bDMARD-experienced patients.

  • ‡Time points for ACR/PASI or ACR/PASI/PsARC.

  • §Studies in bDMARD-experienced patients only and were therefore included in the safety evaluation but not the efficacy evaluation in the base-case analyses.

  • ACR, American College of Rheumatology; bDMARD, biologic disease-modifying antirheumatic drug; BID, two times per day; BIW, twice weekly; HAQ-DI, Health Assessment Questionnaire-Disability Index; IV, intravenously; mTSS, modified Total Sharp Score; PASI, Psoriasis Area and Severity Index; PO, orally; PsA, psoriatic arthritis; PsARC, Psoriatic Arthritis Response Criteria; QxW, every x weeks; SC, subcutaneously.